don t charge extra money for the service, it can eat up your data at a much faster rate each month. while the telecoms companies are betting on the billions they ve ploughed into 56 paying off, they won t be relying on their sales this christmas to bring it all home just yet. that was zoe. now, one in eight women will be diagnosed with breast cancer at some point in their lifetime, making it the most common cancer for women worldwide. and whilst five year survival rates have massively risen, thanks to better treatment and better screening, there is always the fear that, after you ve had treatment to get rid of it, the cancer could come back. mmm. but one company is using al to try and better predict recurrence rates, so that people get treatments that are more suited to them. gustave roussy in paris is one of the world s leading cancer centres, often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies.
this christmas to bring it all home just yet. that was zoe. now, one in eight women will be diagnosed with breast cancer at some point in their lifetime, making it the most common cancer for women worldwide. and whilst five year survival rates have massively risen, thanks to better treatment and better screening, there is always the fear that, after you ve had treatment to get rid of it, the cancer could come back. mmm. but one company is using al to try and better predict recurrence rates, so that people get treatments that are more suited to them. gustave roussy in paris is one of the world s leading cancer centres, often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes
that was zoe. now, one in eight women will be diagnosed with breast cancer at some point in their lifetime, making it the most common cancer for women worldwide. and whilst five year survival rates have massively risen, thanks to better treatment and better screening, there is always the fear that, after you ve had treatment to get rid of it, the cancer could come back. mm, but one company is using al to try and better predict recurrence rates so that people get treatments that are more suited to them. gustave roussy in paris is one of the world s leading cancer centres, often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment
for women worldwide. and whilst five year survival rates have massively risen thanks to better treatment and better screening there is always the fear that after you ve had treatment to get rid of it, the cancer could come back. mm. but one company is using al to try and better predict recurrence rates so that people get treatments that are more suited to them. gustave roussy, in paris, is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health.
gustave roussy in paris is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them. french and us tech company owkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer.